02635nas a2200217 4500008004100000245013400041210006900175260001400244300001200258490000600270520193300276653001702209653001802226653001902244653001302263653002802276653001902304100002302323700002202346856004902368 2017 eng d00aEvaluation of Antidiabetic Activity of Hydroalcoholic Extract of Cassia fistula Linn. pod in Streptozotocin-Induced Diabetic Rats0 aEvaluation of Antidiabetic Activity of Hydroalcoholic Extract of cJuly 2017 a599-6060 v93 a

Background: Diabetes mellitus (DM) is a global health problem and the incidence of DM is increasing at alarming rate all over the world. Many Indian medicinal plants have been reported to possess potential antidiabetic activity and could play important role in the management diabetes. Objective: The present study aimed to evaluate antidiabetic activities of 70% ethanolic extract of Cassia fistula pod in streptozotocin-induced diabetic rats. Materials and Methods: Diabetes was induced in male Wistar rats by single intraperitoneal injection of streptozotocin (60 mg/kg b.wt.). The diabetic rats were administered orally with C. fistula pod extract at three different doses (100, 250 and 500 mg/kg b.wt./day) for 60 days. The results were compared with standard drug glibenclamide (5 mg/kg b.wt./day) treated rats. Results: The streptozotocin treated diabetic control rats showed a significant increase in the blood glucose and glycosylated hemoglobin (HbA1c) levels with a concomitant decrease in the body weight and glycogen content in the liver as compared to normal control rats. Oral administration of C. fistula pod extract (100, 250 and 500 mg/kg b.wt./day) or glibenclamide for 60 days showed significant reduction in the blood glucose and HbA1c levels and an elevation in the body weight and hepatic glycogen content as compared to diabetic control rats. Furthermore, treatment with extract (500 mg/kg b.wt.) also showed improvement of oral glucose tolerance test (OGTT) in diabetic rats. These results were comparable to glibenclamide. Conclusion: The results of present study showed that C. fistula pod extract possess significant antihyperglycemic activity and supports the traditional use of C. fistula pod for the treatment of diabetes mellitus.

10aAntidiabetic10aBlood glucose10aCassia fistula10aGlycogen10aGlycosylated Hemoglobin10aStreptozotocin1 aJangir, Ram, Niwas1 aJain, Gyan, Chand u/files/pj-9-5/10.5530pj.2017.5.95/index.html